BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Cervical cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Treatment
158 results:

  • 1. Comparison of programmed death-ligand 1 expression in adenocarcinoma and squamous cell carcinoma of the cervix in paraffin blocks of patients with cervical cancer.
    Hosseini MS; Shafizadeh F; Bahremani MH; Farzaneh F; Ashrafganjoei T; Arab M; Talayeh M; Jafari F; Abdshah A
    Cancer Rep (Hoboken); 2024 Apr; 7(4):e2057. PubMed ID: 38662366
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Ultrasound-Triggered Azo Free Radicals for cervical cancer Immunotherapy.
    Wang Y; Lv B; Wang H; Ren T; Jiang Q; Qu X; Ni D; Qiu J; Hua K
    ACS Nano; 2024 Apr; 18(17):11042-11057. PubMed ID: 38627898
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Impact of programmed cell death protein 1 inhibitor therapy on the survival of patients with advanced or recurrent uterine cancers: a meta-analysis.
    Liang KW; Chen LJ; Wang CH; Ma KS; Hsia LH; Wang PH
    Front Immunol; 2024; 15():1331994. PubMed ID: 38562939
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-pd-1 therapy resistance.
    Li T; Zhang W; Niu M; Wu Y; Deng X; Zhou J
    Front Immunol; 2024; 15():1342647. PubMed ID: 38550593
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. New windows of surgical opportunity for gynecological cancers in the era of targeted therapies.
    Peters I; Marchetti C; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2024 Mar; 34(3):352-362. PubMed ID: 38438181
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line treatment in Recurrent or Metastatic cervical cancer (COMPASSION-13): A Phase 2 Study.
    Lou H; Cai H; Huang X; Li G; Wang L; Liu F; Qin W; Liu T; Liu W; Wang ZM; Li B; Xia Y; Wang J
    Clin Cancer Res; 2024 Apr; 30(8):1501-1508. PubMed ID: 38372727
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Clinical benefit analysis of pd-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review.
    Wang YZ; Wang JS; Du J; Tang XL; Xiao JP
    Front Immunol; 2024; 15():1305810. PubMed ID: 38327524
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Prevalence of PD-L1 in cervical cancer Patients and the Potential for Combining an Immune Checkpoint Inhibitor With Lenvatinib.
    Bräutigam K; Schmidt T; Baur M; Tauber N; Kontomanolis EN; Hemptenmacher F; Rody A; Köster F
    Anticancer Res; 2024 Feb; 44(2):503-510. PubMed ID: 38307554
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Whether specific genetic feature predicted immunotherapy efficacy: A case report.
    Chen J; Pang L; He L; Li T; Cheng X
    Medicine (Baltimore); 2024 Jan; 103(2):e36922. PubMed ID: 38215117
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report.
    Passarelli A; Pisano C; Coppola E; Ventriglia J; Cecere SC; Di Napoli M; Carideo L; Lastoria S; Pignata S
    Front Immunol; 2023; 14():1303893. PubMed ID: 38193091
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review.
    Zhai C; Jin X; You L; Yan N; Dong J; Qiao S; Zhong Y; Zheng Y; Pan H
    BMC Geriatr; 2024 Jan; 24(1):32. PubMed ID: 38191289
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. An Immune Gene Expression Risk Score for Distant Metastases after Radiotherapy for cervical cancer.
    Lukovic J; Pintilie M; Han K; Fyles AW; Bruce JP; Quevedo R; Pugh TJ; Fjeldbo CS; Lyng H; Milosevic MF
    Clin Cancer Res; 2024 Mar; 30(6):1200-1207. PubMed ID: 38180733
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Linking tumor immune infiltrate and systemic immune mediators to treatment response and prognosis in advanced cervical cancer.
    Rocha Martins P; Luciano Pereira Morais K; de Lima Galdino NA; Jacauna A; Paula SOC; Magalhães WCS; Zuccherato LW; Campos LS; Salles PGO; Gollob KJ
    Sci Rep; 2023 Dec; 13(1):22634. PubMed ID: 38114557
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Case report: Leptomeningeal metastasis of advanced nasopharyngeal carcinoma treated with chemoimmunotherapy.
    Shi M; Sun D; Ma X; Liu J; Zhang Y; Liu T; Chen X; Mo S; Zhao Y; Zhang L
    Hum Vaccin Immunother; 2023 Dec; 19(3):2294579. PubMed ID: 38111107
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The role of BATF2 deficiency in immune microenvironment rearrangement in cervical cancer - New biomarker benefiting from combination of radiotherapy and immunotherapy.
    Zong Y; Chang Y; Huang K; Liu J; Zhao Y
    Int Immunopharmacol; 2024 Jan; 126():111199. PubMed ID: 37995570
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The effects of 5-aminolevulinic acid photodynamic therapy on the local immune response of women with cervical intraepithelial neoplasia grade 2.
    Wu A; Niu J; Hong Z; Gu L; Huang Y; Qiu L
    Front Immunol; 2023; 14():1211114. PubMed ID: 37928525
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. A Therapeutic DNA Vaccine Targeting HPV16 E7 in Combination with Anti-pd-1/PD-L1 Enhanced Tumor Regression and Cytotoxic Immune Responses.
    Han X; Gao Z; Cheng Y; Wu S; Chen J; Zhang W
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895145
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.
    Shi YY; Dong DR; Fan G; Dai MY; Liu M
    Front Immunol; 2023; 14():1237964. PubMed ID: 37849747
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Immunotherapies landscape and associated inhibitors for the treatment of cervical cancer.
    Yadav A; Yadav S; Alam MA
    Med Oncol; 2023 Oct; 40(11):328. PubMed ID: 37815596
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 8.